Sooyoung Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5050876/publications.pdf

Version: 2024-02-01

516215 500791 61 913 16 28 citations h-index g-index papers 62 62 62 1127 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Females with impaired ovarian function could be vulnerable to environmental pollutants: identification via next-generation sequencing of the vaginal microbiome. Journal of Obstetrics and Gynaecology, 2022, 42, 1482-1488.	0.4	O
2	Fatty Acid Metabolism in Ovarian Cancer: Therapeutic Implications. International Journal of Molecular Sciences, 2022, 23, 2170.	1.8	34
3	Role of Artificial Intelligence Interpretation of Colposcopic Images in Cervical Cancer Screening. Healthcare (Switzerland), 2022, 10, 468.	1.0	6
4	Integration of Genomic Profiling and Organoid Development in Precision Oncology. International Journal of Molecular Sciences, 2022, 23, 216.	1.8	1
5	Analysis of the Relationship between Socioeconomic Status and Incidence of Hysterectomy Using Data of the Korean Genome and Epidemiology Study (KoGES). Healthcare (Switzerland), 2022, 10, 997.	1.0	2
6	Fertility preservation for patients with cancer. Journal of the Korean Medical Association, 2022, 65, 329-337.	0.1	0
7	Learning curve could affect oncologic outcome of minimally invasive radical hysterectomy for cervical cancer. Asian Journal of Surgery, 2021, 44, 174-180.	0.2	23
8	Isolated cortical vein thrombosis in an infertile male taking clomiphene citrate. Neurological Sciences, 2021, 42, 1615-1616.	0.9	3
9	Changes in telomere length and senescence markers during human ovarian tissue cryopreservation. Scientific Reports, 2021, 11, 2238.	1.6	9
10	Current and Future Perspectives for Improving Ovarian Tissue Cryopreservation and Transplantation Outcomes for Cancer Patients. Reproductive Sciences, 2021, 28, 1746-1758.	1.1	20
11	The Effectiveness of Anti-Apoptotic Agents to Preserve Primordial Follicles and Prevent Tissue Damage during Ovarian Tissue Cryopreservation and Xenotransplantation. International Journal of Molecular Sciences, 2021, 22, 2534.	1.8	13
12	Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage. International Journal of Molecular Sciences, 2021, 22, 7484.	1.8	34
13	Genomic Consideration in Chemotherapy-Induced Ovarian Damage and Fertility Preservation. Genes, 2021, 12, 1525.	1.0	2
14	Role of Stem Cells in the Ovarian Tissue Cryopreservation and Transplantation for Fertility Preservation. International Journal of Molecular Sciences, 2021, 22, 12482.	1.8	2
15	Role of Klotho as a Modulator of Oxidative Stress Associated with Ovarian Tissue Cryopreservation. International Journal of Molecular Sciences, 2021, 22, 13547.	1.8	9
16	WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer. Anticancer Research, 2020, 40, 6017-6028.	0.5	7
17	Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity. International Journal of Molecular Sciences, 2020, 21, 7792.	1.8	25
18	Learning curve for sentinel lymph node mapping in gynecologic malignancies. Journal of Surgical Oncology, 2020, 121, 599-604.	0.8	22

#	Article	IF	CITATIONS
19	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget, 2020, 11, 3035-3047.	0.8	4
20	Comparing efficacy of high-dose rate brachytherapy versus helical tomotherapy in the treatment of cervical cancer. Journal of Gynecologic Oncology, 2020, 31, e42.	1.0	4
21	Different types of multipleâ€synapse boutons in the cerebellar cortex between physically enriched and ataxic mutant mice. Microscopy Research and Technique, 2019, 82, 25-32.	1.2	10
22	Comparison between Slow Freezing and Vitrification for Human Ovarian Tissue Cryopreservation and Xenotransplantation. International Journal of Molecular Sciences, 2019, 20, 3346.	1.8	59
23	Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An openâ€label, multicenter, randomized study. Journal of Obstetrics and Gynaecology Research, 2019, 45, 858-864.	0.6	17
24	Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study. Journal of Obstetrics and Gynaecology Research, 2019, 46, 337-346.	0.6	4
25	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, <i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncolmmunology, 2019, 8, e1512455.	2.1	17
26	Effect of postoperative adjuvant treatment in the therapeutic management of stage I, morcellated uterine leiomyosarcoma: A Korean multicenter study Journal of Clinical Oncology, 2019, 37, e17106-e17106.	0.8	0
27	Scalp metastasis from endometrial carcinoma: a case report and literature review. Journal of Obstetrics and Gynaecology, 2018, 38, 1181-1182.	0.4	2
28	Ruxolitinib significantly enhances <i>in vitro</i> apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. Oncotarget, 2018, 9, 9776-9788.	0.8	17
29	Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. Journal of Gynecologic Oncology, 2018, 29, e56.	1.0	20
30	Analysis of Anticancer Activity and Chemical Sensitization Effects of <i>Dendropanax morbifera</i> and <i>Commersonia bartramia</i> Extracts. Anticancer Research, 2018, 38, 3853-3861.	0.5	4
31	Ovarian tissue cryopreservation and transplantation in patients with cancer. Obstetrics and Gynecology Science, 2018, 61, 431.	0.6	64
32	A gonadotropin-releasing hormone agonist for the prevention of docetaxel-induced gonadal damage. Journal of Obstetrics and Gynaecology, 2017, 37, 783-789.	0.4	5
33	Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. British Journal of Haematology, 2017, 177, 601-611.	1.2	15
34	Three-dimensional computed tomography as a novel method for the diagnosis and management of obstructed hemivagina and ipsilateral renal anomaly syndrome: A case report. Journal of Obstetrics and Gynaecology, 2017, 37, 390-391.	0.4	1
35	Fertility preservation for patients with gynecologic malignancies: The Korean Society for Fertility Preservation clinical guidelines. Clinical and Experimental Reproductive Medicine, 2017, 44, 175.	0.5	14
36	The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. Oncotarget, 2017, 8, 27839-27853.	0.8	31

#	Article	IF	CITATIONS
37	Management of atypical squamous cells of undetermined significance or lowâ€grade squamous intraepithelial lesions of the uterine cervix with human papilloma virus infection among young women aged less than 25 years. Diagnostic Cytopathology, 2016, 44, 959-963.	0.5	6
38	Paratubal Borderline Malignancy: A Case of a 17-Year-Old Adolescent Female Treated with Laparo-Endoscopic Single-Site Surgery and a Review of the Literature. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 74-76.	0.3	10
39	Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude Highâ€Grade Squamous Intraepithelial Lesion. Oncologist, 2015, 20, 635-639.	1.9	3
40	Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL. Blood, 2015, 126, 4852-4852.	0.6	1
41	Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL. Blood, 2015, 126, 5117-5117.	0.6	3
42	Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act As a Tumor Suppressor Gene in Pediatric BL. Blood, 2015, 126, 3656-3656.	0.6	0
43	Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-Cell Lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May be a Potential Adjuvant Agent in the Treatment of PMBL and of HL. Blood, 2015, 126, 2732-2732.	0.6	0
44	Clinical significance of <scp>HPV DNA</scp> cotesting in <scp>Korean</scp> women with <scp>ASCUS</scp> or <scp>ASCâ€H</scp> . Diagnostic Cytopathology, 2014, 42, 1058-1062.	0.5	8
45	Obinutuzumab (GA101) Significantly Inhibits Cell Proliferation and Induces Programmed Cell Death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May be a Future Targeted Agent for the Treatment of PMBL. Blood, 2014, 124, 4492-4492.	0.6	1
46	Assessment of cervical cancer screening policy in Korea for women over age 65. Journal of Geriatric Oncology, 2013, 4, 382-387.	0.5	9
47	Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL. Blood, 2013, 122, 3852-3852.	0.6	2
48	Obinutuzumab (GA101), a Novel Type II Glycoengineered CD20 Antibody, Significantly Induced Programmed Cell Death In Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May Be a Future Potential Targeted Agent For The Treatment Of PMBL. Blood, 2013, 122, 5146-5146.	0.6	1
49	Sequence-Specific Talens-Induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases Phosphorylation Of AKT and Ikba In Pediatric Burkitt Lymphoma (PBL): DLEU1 May Act As a Tumor Suppressor Gene In PBL. Blood, 2013, 122, 1279-1279.	0.6	O
50	Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis. Blood, 2013, 122, 2503-2503.	0.6	0
51	Transcription Activator Like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model. Blood, 2013, 122, 4883-4883.	0.6	0
52	Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity. Blood, 2013, 122, 243-243.	0.6	5
53	Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertility and Sterility, 2012, 97, 671-676.	0.5	72
54	Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer?. Fertility and Sterility, 2012, 98, 961-964.e1.	0.5	48

Sooyoung Kim

#	Article	IF	CITATIONS
55	Fertility preservation in women with cancer. Clinical and Experimental Reproductive Medicine, 2012, 39, 46.	0.5	22
56	JAK1/JAK2 Inhibitor, Ruxolitinib Inhibits Cell Proliferation and Induces Apoptosis in Hodgkin Lymphomas (HL) and Primary Mediastinal B-Cell Lymphomas (PMBL). Blood, 2012, 120, 4886-4886.	0.6	3
57	Talens-Mediated DLEU1 Gene Silencing in Burkitt Lymphoma (BL): Implication of Lncrna DLEU1 Gene As a Potential Tumor Suppressor Gene in BL Blood, 2012, 120, 2403-2403.	0.6	0
58	Overexpression of Deleted Lymphocytic Leukemia 1 (DLEU1) Inhibits Proliferation of Burkitt Lymphoma (BL) Blood, 2012, 120, 2654-2654.	0.6	0
59	Determinants of access to fertility preservation in women with breast cancer. Fertility and Sterility, 2011, 95, 1932-1936.	0.5	60
60	Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. Journal of Assisted Reproduction and Genetics, 2011, 28, 651-656.	1.2	22
61	Value of Early Referral to Fertility Preservation in Young Women With Breast Cancer. Journal of Clinical Oncology, 2010, 28, 4683-4686.	0.8	137